Business
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO® (selinexor) and Provides Commercial Update
-- XPOVIO Unaudited Net Product Sales of between $17 and $18 Million for Fourth Quarter 2019 and between $30 and $31 Million for the Full Year 2019 -- --
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"-- XPOVIO Unaudited Net Product Sales of between $17 and $18 Million for Fourth Quarter 2019 and between $30 and $31 Million for the Full Year 2019 --\n -- Approximately 1,400 XPOVIO Prescriptions Fulfilled in the U.S. from Launch Through Year End 2019 -- NEWTON, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced preliminary unaudited fourth quarter and full year 2019 net product sales for XPOVIO® (selinexor), the Company’s first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) compound, and provided additional updates on the product’s commercial launch. Strong XPOVIO Commercial Rollout Continues in the U.S. Oral XPOVIO tablets became commercially available to patients in the U.S. on July 9, 2019. Based on preliminary unaudited financial information, Karyopharm expects net product sales of XPOVIO to be between $17 and $18 million during the fourth quarter and between $30 and $31 million for the full year 2019. As of December 31, 2019, approximately 1,400 XPOVIO prescriptions have been fulfilled, driven by strong demand from both academic and community-based oncologists. In less than 6 months on the market, XPOVIO has been prescribed by more than 550 unique physicians and healthcare accounts. These updates will be discussed during a webcast presentation at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, 2020 at 10:00 a.m. PT (1:00 p.m. ET). A live webcast of the presentation and Q&A session can be accessed through the investor section of the Company’s website at www.karyopharm.com. Following the live presentation, a replay of the webcast will be available on the Company’s website for 30 days. “By all accounts, 2019 was a transformational year for Karyopharm with the accelerated approval and commercial launch of XPOVIO, the first and only oral nuclear export inhibitor approved in the U.S., indicated for patients with heavily pretreated multiple myeloma,” said Michael G. Kauffman, MD, PhD, Chief Executive Officer of Karyopharm. “We are extremely pleased with the commercial launch of XPOVIO thus far, including the breadth of prescribing physicians and early feedback from patients who have initiated therapy. We are proud to be making such an important impact for patients who are battling ...